Embed Size (px)
Citation preview
RealTime Dynamix™: Rheumatoid Arthritis EU Q1 2017
With the recent approval of two new JAK inhibitors and the imminent introduction of additional
IL-6 inhibitors, EU rheumatologists anticipate substantial practice shifts in RA management.
Spherix Global Insights recently released data collected from 257 rheumatologists
in France, Germany, Italy, Spain and the UK, revealing a high unmet need for small molecules and
alternate mechanism biologics for the treatment of rheumatoid arthritis (RA). Check out some
highlights from this report:
RealTime Dynamix™: provides rapid response trending on the key issues affecting the Rheumatology market.
Every other quarter ~250 qualified EU-based rheumatologists participate in an online survey.
For more information contact: [email protected]
Surveyed rheumatologists across all EU5 countries reported RA practice shifts, with the majority
noting the introduction of biosimilars
Invest In Intelligence That Delivers
Similar to the US, the established SC TNF
inhibitors, etanercept and adalimumab, capture
the greatest biologic share across the EU5…
...However, unlike the US, RoActemra
accounts for the third greatest proportion of
share, capturing 12% of EU5 RA biologics use.
...When asked to choose
between a new JAK or new
IL-6 inhibitor for the treatment
of RA, nearly three-quarters of
respondents opted for a new
JAK
However, when pinned against the first approved JAK
on the EU market, Olumiant, rheumatologists would
prefer Olumiant over Xeljanz
2:1
With the recent approvals of Eli
Lilly/Incyte’s Olumiant and
Pfizer’s Xeljanz, they will be
getting what they want
With RoActemra’s deeper penetration in the EU5 market, the IL-6 inhibitors in development, Sanofi/
Regeneron’s Kevzara (sarilumab) and Janssen/GSK’s sirukumab, have a potential opportunity to
capitalize on converting RoActemra share. Indeed, over one-quarter of EU5 rheumatologists believe
the new IL-6 inhibitors will be completely interchangeable with RoActemra. However...
